Project Grant HT94252310208

This $666,380 Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop a novel cell therapy for treating intractable epilepsy. The funded project aims to scale up production of synchronized early postmitotic human cortical interneurons (CINs) derived from pluripotent stem cells under cGMP...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $499,953 to Stem Pharm, Inc. to develop and validate a central nervous system (CNS) organoid model of temporal lobe epilepsy (TLE) for drug discovery. The project aims to create a reproducible, 96-well plate format human stem cell-derived neural organoid system that...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 5-year, $690,763 Project Grant (CFDA 93.853: Extramural Research Programs in the Neurosciences and Neurological Disorders) to Brigham & Women's Hospital Inc. to optimize neuromodulation therapies for epilepsy patients. The project aims to identify factors that determine patient response to Responsive Neurostimulation (RNS), a treatment for drug-resistant epilepsy, focusing on 3 key objectives: 1) analyzing...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research to deepen the understanding of how electrical stimulation of the anterior nucleus of the thalamus (ANT-DBS) can reduce seizures in patients with drug-resistant epilepsy. The $546,626 award to Emory University aims to identify the specific neuronal network components...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $461,701 to Tega Therapeutics Inc. to develop and validate an intracerebroventricular (ICV) enzyme replacement therapy for the treatment of GM1 gangliosidosis, a rare lysosomal storage disease affecting the central nervous system. The key objectives are to engineer cell lines to...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $323,001 to Axonis Therapeutics, Inc. to develop an oral KCC2 potentiator compound, AXN-027, as a potential novel anti-epileptic drug for treating mesial temporal lobe epilepsy (MTLE). The funding will support preclinical research using a mouse model of MTLE to investigate the...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $221,120.00 to the University of Texas Health Science Center at Houston (UTHealth) to conduct research on improving neural progenitor cell survival and migration in the context of neurodegenerative diseases and brain injuries, such as stroke. The research investigates...

The University of Pittsburgh is conducting a $420,685 project grant titled "Accelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment" funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). This two-year project seeks to explore the use of accelerated intermittent theta burst stimulation (iTBS) to enhance working memory and functional connectivity in individuals with treatment-resistant...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $363,602 to Tulane University to develop improved screening methods for anti-seizure medications using Drosophila (fruit fly) models of drug-resistant epilepsy. The project aims to enhance in vivo screening capabilities by optimizing video tracking and electrophysiology techniques in...

This $143,244 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program will support research to characterize the impact of SCN8A epileptic encephalopathy mutations on parvalbumin (PV) interneuron function. The research aims to determine whether aberrant PV interneuron excitability contributes to seizures in SCN8A epileptic...